Frustrating as all this is. There are a couple of views to be taken here.
one meso actually are in advanced discussions with other pharma and the other pharma are trying to buy whatever indication for whatever price.
id be looking to lowball meso because I can. They have no money, they are burning cash.
two, the banks have said no to anymore funds.
three the banks have reduced facility, but the use of funds doesn't state that, so U have to imagine they'd be in all sorts of trouble saying they are using the funds for specific reasons when if the main reason is they are calling in the loans.
i can't afford to buy more shares, so I'll accept dilution and have a future value, than have to company go under and have no value at all.
if this helps the company extend the runway, so be it, so long as there is a chance of approval at some point.
people on here have complained about not being part of past raises. You are now, so have a p15s or get off the pot.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Completes Institutional Allocation
MSB
mesoblast limited
Add to My Watchlist
0.93%
!
$1.63

Ann: Mesoblast Completes Institutional Allocation, page-64
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B |
Open | High | Low | Value | Volume |
$1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 707 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 7320 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11200 | 1.625 |
11 | 72699 | 1.620 |
1 | 30000 | 1.615 |
7 | 58298 | 1.610 |
3 | 96589 | 1.605 |
Price($) | Vol. | No. |
---|---|---|
1.635 | 7000 | 1 |
1.640 | 17668 | 3 |
1.645 | 7000 | 1 |
1.650 | 37309 | 4 |
1.655 | 40000 | 2 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online